Biocon, Warnex, PRO-DNA, Third Wave, Applera, ABI, FDA, Affy, CombiMatrix, Geneservice | GenomeWeb

India-based Biocon Files for EGFR Drug Approval from India Regulators

Biocon said last week that it intended to file for regulatory approval of its EGFR-targeting drug Biomab from the government of India in May, with possible approval by the end of the year. The company made no mention of pharmacogenomic uses of the monoclonal antibody compound, although there is evidence that response to EGFR inhibitors can be associated with genetic or protein biomarkers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.